Tokyo, July 3 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062116) titled 'Estimating Trial-Eligible CKD Populations for Major Kidney Outcome Trials and SGLT2 Inhibitor Benefits in Japan: A Descriptive Analysis and Projection of SGLT2 Inhibitor Prescription and Potential Reductions in ESKD and Cardiovascular Events' on July 2.
Study Type:
Observational
Primary Sponsor:
Institute - Nippon Boehringer Ingelheim Co., Ltd.
Condition:
Condition - Chronic Kidney Disease (CKD)
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To estimate the number of CKD patients across Japan meeting the eligibility criteria of major sodium-glucose cotransporter 2...